Abstract
the objective of this work is to present a series of cases of COVID-19 with atypical manifestations of the disease. The cases were evaluated by an interdisciplinary team of health personnel from a fourth-level clinic in Barranquilla, Colombia, and the data was subsequently taken from the clinical history of each patient. Three cases were evaluated, initially the first case with torpid evolution, coinfection with H1N1 influenza virus, however, with satisfactory outcome, and cases two and three with gastrointestinal manifestations as disease debut, with satisfactory evolution. The SARS-CoV-2 pandemic takes more lives every day, so it is necessary to describe the cases and their diverse variety of presentation, to identify the infected and take both therapeutic and preventive measures. To prevent the spread of the disease and achieve its control.
References
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the Coronavirus Study Group. BioRxiv. 2020 [citado May 2020]. Dispomible en: https:// www.biorxiv.org/content/10.1101/2020.02.07.937862v1.full.
Organización Mundial de la Salud (OMS). Nuevo coronavirus- China. Ginebra: OMS; 2020.
World Health Organization (WHO). Coronavirus disease 2019 - Situation report 114. Geneve: WHO; 2020 [citado May 2020]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Colombia. Instituto Nacional de Salud (INS). COVID-19 Colombia. Reporte 06-05-2020. Bogotá D.C.: INS; 2020.
Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol. 2019;73(1):529-57.
Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses. 2019;11(1):41.
https://doi.org/10.3390/v11010041.
Arabi YM, Asiri AY, Assiri AM, Aziz-Jokhdar HA, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020;21(1):8. https://doi.org/10.1186/s13063-019-3846-x.
Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313-24. https://doi.org/10.4014/jmb.2003.03011.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;381(18):1708-20. https://doi.org/10.1056/NEJMoa2002032.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel CoronavirusInfected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585.
Joseph T, Moslehi MA. International pulmonologist’s consensus on COVID-19. 2020.
Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648.
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus(2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-7. https://doi.org/10.1002/jmv.25689.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-207. https://doi.org/10.1056/NEJMoa2001316.
Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020;133(9):1015-24. https://doi.org/10.1097/CM9.0000000000000722.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirusin Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Rothan HA, Byrareddy SN. The epidemeology and pathogensis of coronavirus (Covid-19) outbreak. J Autoimmun. 2020;109:02433. https://doi.org/10.1016/j.jaut.2020.102433.
Otto A. Unusual Presentations of COVID-19: “Our Ignorance Is Profound.” medscape. 2020;1-2.
Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and Liver Manifestations of COVID-19. J Clin Exp Hepatol. 2020;10(3):2637-5. https://doi.org/10.1016/j.jceh.2020.03.001.
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID19. Kidney Int. 2020;97(5):829-38. https://doi.org/10.1016/j.kint.2020.03.005.
Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. Am J Roentgenol. 2020;(1):1-6. https://doi.org/10.2214/AJR.20.22961.
Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.4683.
Azekawa S, Namkoong H, Mitamura K, Kawaoka Y, Saito F. Co-infection with SARS-CoV-2 and influenza A virus. IDCases. 2020;20:e00775. https://doi.org/10.1016/j.idcr.2020.e00775.
Tang X, Du RH, Wang R, Cao TZ, Guan LL, Yang CQ, et al. Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1. Chest. 2020; S0012-3692(20)30558-4. https://doi.org/10.1016/j.chest.2020.03.032.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.
Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2020;2842. https://doi.org/10.1101/2020.03.30.20048058.